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More than 70% of the general population worldwide has serological evidence of exposure to Polyomavirus hominis type 1,
better known as BK virus (BKV). BKV infection typically occurs during childhood, without specific symptoms, followed by
a state of nonreplicative infection in various tissues, with the urogenital tract as the principal site. Asymptomatic reactivation
and low-level replication with viruria is observed in 5% of healthy individuals. Persistent high-level BKV replication is the
hallmark of polyomavirus-associated nephropathy in renal transplantation and of hemorrhagic cystitis in bone marrow
transplantation. Since these manifestations are rare in other types of immunocompromised patients, the presence of specific
cofactors is postulated. The role of BKV in autoimmune disease and cancer is a controversial topic and is difficult to determine,
because the pathology no longer depends on BKV replication. This article discusses current views of pathogenesis, diagnosis,
and treatment
In the past decade, the human polyomavirus type 1, named
“BK virus” (BKV) after the initials of the first affected patient,
surfaced as a significant pathogen in kidney transplant recip-
ients by causing polyomavirus-associated nephropathy (PVAN)
[1, 2]. Increasing prevalence rates of PVAN (1%–10%) have
been reported since then, with allograft dysfunction and loss
in 150% of cases [3, 4]. Thus, PVAN is viewed as one of the
leading causes of renal allograft loss in the first 2 years after
transplantation. Although BKV was discovered as early as 1970,
the pathologic significance of BKV in human diseases remained
essentially confined to an association with late-onset hemor-
rhagic cystitis in bone marrow transplantation, the specificity
of which has been questioned [4]. This clearly distinguished
BKV from the other human polyomavirus type 2, JC virus
(JCV), also named after the initials of the first patient. JCV
was eagerly hunted for, after particles of typical polyomavirus
morphology had been detected in 1965 by electron microscopy
in brain lesions from patients with progressive multifocal leu-
koencephalopathy, a rare demyelinating disease first described
in immunocompromised patients in 1958. However, new di-
agnostic tools—in particular, identification and quantification
of BKV in plasma, proved useful in diagnosis and management
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of PVAN [5, 6] and are now available to reevaluate the path-
ogenic role of BKV in other risk groups and diseases [7].
EPIDEMIOLOGICAL ASPECTS
The combined virological, epidemiological, and clinical data
(i.e., the high prevalence of infection, low morbidity, asymp-
tomatic reactivation, and host specificity) suggest coevolution-
ary adaptation of BKV and the human host [4]. Primary in-
fection typically occurs during early childhood, after the waning
of maternal antibodies. Before the age of 10 years, the sero-
prevalence increases to 50%, and it reaches 170% in adults [8].
JCV antibody prevalence shows a similar but slightly delayed
pattern, indicating independent transmission despite consid-
erable genetic homology of 70%. Exposure to the polyomavirus
of Rhesus macaques, SV40, resulted from contaminated polio-
virus and adenovirus vaccines in the 1960s and may still be
ongoing in zoos and animal parks [9], but widespread circu-
lation among humans is not supported by serological data [8].
The natural route of BKV transmission has not been resolved
and may be respiratory or oral. BKV, like JCV, is fairly resistant
to environmental inactivation, and both have been detected in
human sewage. A state of nonreplicative infection, termed “la-
tency,” is established in renal tubular epithelial and urothelial
cells. Reactivation and low-level replication with asymptomatic
viruria occurs in 5% of healthy individuals [4]. The prevalence
may increase with pregnancy, older age, or immune dysfunc-
tion, to rates of 160%. In addition, the level of replication may
increase to a BKV DNA load from !105 to 1107 copies/mL of
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Table 1. Terminology used in the present study of BK virus
(BKV).
Term Definition
BKV infection Case with serological or virological evidence of
virus exposure, including replicative and nonre-
plicative states
BKV replication Case with evidence of virus multiplication (active
or lytic infection) obtained by detection of infec-
tious virus, virions, structural proteins or their
mRNA, or cell-free DNA in nonlatency sites
(e.g., plasma or CSF); by cytological analysis
(of decoy cells); or by histological analysis
BKV disease Case with histological evidence of BKV-mediated
organ pathology
urine. However, BKV disease is rare, which suggests that ad-
ditional factors are required.
VIROLOGICAL ASPECTS
BKV belongs to the genus Polyomavirus of the family Poly-
omaviridae, which is defined by a typical morphology of non-
enveloped virions with icosahedral capsids with a 40-nm di-
ameter that enclose the small circular double-stranded DNA
genome of 5 kb. The genome architecture is conserved and
consists of the noncoding control region that contains the or-
igin of replication and bidirectional promoters, the early genes
encoding the small tumor antigen and the large tumor antigen
(LTag), and the late genes encoding the viral capsid proteins
(VP1–VP3) and the agnoprotein. LTag is a conserved multi-
functional regulator of polyomavirus transcription and repli-
cation. LTag interacts with host cell proteins, including the
tumor-suppressor gene products p53 and retinoblastoma pRb,
and it subverts host cell division to recruit factors for viral
DNA replication [10]. Unlike replication of herpesviruses, po-
lyomavirus replication is largely dependent on host cell factors
and, with the exception of LTag DNA helicase, does not encode
typical antiviral drug targets, such as thymidine kinases or viral
DNA polymerase. The close virus-host relationship is illustrated
by polyomavirus genomes forming chimeric nucleosomes with
host cell histones, which are packaged into viral particles. In
replication-permissive cells, expression of the viral capsid pro-
teins is followed by virion assembly in the nucleus, which even-
tually results in host cell lysis to release infectious progeny.
Thus, BKV replication is cytopathic. The release of viral and
cellular constituents elicits a nonspecific inflammatory reaction,
followed by specific humoral and cellular immune responses
in immunocompetent hosts [4].
BKV DISEASE
High prevalence, latent infection, and asymptomatic reactiva-
tion of BKV complicate the appreciation of its pathogenic role.
Thus, for the purposes of the present study, the terms “BKV
infection,” “BKV replication,” and “BKV disease” are defined
in table 1.
Polyomavirus infections have been associated with diverse
pathologies. In particular, the association of BKV with auto-
immune disease and cancer is controversial, which reflects the
difficulty of confirming histopathologic definitions of BKV dis-
ease; nevertheless, I present some hypotheses here (figure 1).
In autoimmune disease, polyomavirus replication is thought
to trigger a pathologic immune response. In experimental stud-
ies, autoimmune responses could be induced by exposure to
viral DNA-protein complexes involving histones or LTag [11],
and an association between BKV and systemic lupus erythe-
matodes has been proposed. The hypothetical role of BKV in-
fection in autoimmune disease is not specific, and exposure to
other infectious and noninfectious antigens might elicit a sim-
ilar response in a predisposed patient. It is likely that as-yet
undefined (immuno)genetic determinants and/or circum-
stances of infection provide necessary cofactors [11].
In oncogenic disease, activation of host cell replication in-
duced by viral proteins like LTag is uncoupled from viral late-
gene expression, virion assembly, and subsequent host cell lysis
[10]. Hypothetically, uncoupling from viral late-gene expres-
sion might occur either genetically, by chromosomal integra-
tion, or functionally, by interference with concerted late-gene
expression. Although cases of metastatic urothelial carcinoma
[12], adenocarcinoma [13], and early-stage prostate neoplasia
[14] have been discussed in support of experimentally dem-
onstrated oncogenic potential of BKV, the diagnosis of the role
of BKV infection as “driver,” “innocent passenger,” or transient
“hit and run” agent is difficult to prove with the current di-
agnostic tools.
Given the high prevalence of BKV infection in the human
population, it seems that a potential role, if any, of BKV au-
toimmune and oncogenic disease must require as-yet undefined
genetic or acquired cofactors. It is important to emphasize,
with regard to conceptual and diagnostic concerns, that the
pathogenesis of both mechanisms no longer requires ongoing
BKV replication. By contrast, high-level BKV replication is a
hallmark of diseases such as PVAN and hemorrhagic cystitis
and may serve as a noninvasive diagnostic marker for screening
and monitoring.
BKV-ASSOCIATED ORGAN MANIFESTATIONS
Kidney. Kidney manifestations are not well defined in im-
munocompetent individuals, although latent polyomavirus in-
fection presumably follows primary viremic seeding. Even in
immunocompromised patients, BKV disease of autologous kid-
neys is restricted to rare cases. Nevertheless, one of the first
reported cases of tubulo-interstitial nephritis (or PVAN pattern
B) progressing to fibrosis and tubular atrophy (or PVAN pattern
C) was observed in a child with hyper-IgM syndrome, most
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Figure 1. Patterns of polyomavirus (PV) pathology during virus replication and immune response. A colon (:) indicates interaction. BKV, BK virus;
BMT, bone marrow transplantation; HC, hemorrhagic cystitis; JCV, JC virus; LTag, large T antigen; PML, progressive multifocal leukoencephalopathy;
PVAN-A and PVAN-B, polyomavirus-associated nephropathy patterns A and B, respectively.
likely after primary replication [15]. PVAN is rare in other
transplantation procedures, including solitary pancreas [16],
heart [17], lung [18], and hematopoietic stem cell [19] trans-
plantations, despite the use of similar or more intense im-
munosuppression in the transplant recipients. The emergence
of PVAN in renal transplantation represents a new challenge
from an old companion and emphasizes the role of renal al-
lograft–specific determinants and opportunities in the patho-
genesis of PVAN.
The diagnosis of PVAN requires the histological demonstra-
tion of BKV replication and organ damage. Renal tubular ep-
ithelial cells typically show enlarged nuclei with amorphous,
basophilic viral inclusions [20, 21]. Variant inclusions have also
been described, and immunohistochemical staining for LTag is
widely used as a confirmatory assay. Histological studies in-
dicate that PVAN progresses through presentations that are
initially predominantly cytopathic (pattern A), followed by a
cytopathic-inflammatory stage without significant fibrosis (pat-
tern B) and a late stage with predominant tubular atrophy and
fibrosis (pattern C). PVAN patterns B and C were significantly
associated with allograft loss [22]. This provided independent
evidence in support of the notion that early diagnosis of PVAN
is associated with improved outcome after reduction of im-
munosuppression [6, 23, 24].
The risk factors for PVAN in renal transplantation are con-
troversial, which may be a reflection of methodological differ-
ences between the various studies. In addition, it seems likely
that PVAN requires multiple synergizing factors that include
characteristics of the patient (i.e., older age, male sex, white
race, negative serostatus before transplantation, and diabetes),
of the transplant (i.e., HLA-mismatches, prior acute rejections,
ischemia, and calcineurin-inhibitor toxicity), and of the virus
(i.e., serotype, genome mutations and rearrangements, immune
evasion, and fitness) [4, 25]. However, immunosuppression is
generally accepted as the key modulator that increases the risk,
relative to its potency, and that permits unchecked high-level
replication [26]. Practically all cases of PVAN have been di-
agnosed in patients who were receiving triple combinations of
drugs from 4 classes of immunosuppressive agents. The co-
incidence of PVAN with the widespread use of tacrolimus and
mycophenolate mofetil (MMF) has caused much debate [27].
It has been pointed out elsewhere that neither drug is necessary
for PVAN to occur, because PVAN has been observed in patients
who were not receiving tacrolimus or MMF [2]. Reflecting the
potency, however, BKV replication is significantly associated
with combinations of tacrolimus and MMF, compared with
other drug combinations [28].
There are 4 issues of particular interest with regard to an-
tiviral immune control and transplantation.
1. Increasing HLA-mismatches, prior rejection episodes,
and intensification of immunosuppression by antirejection
treatment, including an increasing number of steroid pulses,
were associated with BKV replication and disease in a pro-
spective study [6] and in a case-control study [29] but were
not found to be associated in other studies [30, 31].
2. BKV-seronegative transplant recipients, particularly
those who are pediatric patients, are at increased risk for BKV
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replication and PVAN [32, 33], but seropositive recipients are
not protected from BKV viremia or disease [6]. In patients with
PVAN, BKV-specific T cells were not detectable in the periph-
eral blood, and, after reduction of immunosuppression, they
(re)appeared in 2 patients after clearance of BKV viremia and
resolution of PVAN [34]. These data suggest that BKV-specific
T cell response might provide information that would com-
plement the data on BKV load in plasma.
3. Cytomegalovirus (CMV) replication has been suggested
to promote BKV, either directly or indirectly [35]. However,
no correlation was observed in a detailed study of CMV- and
BKV-seropositive patients who did not receive CMV prophy-
laxis [6]. Unlike CMV, BKV replication and disease were not
associated with the use of antilymphocyte globulin when it was
administered for induction but were associated when it was
given as rejection treatment [6], which suggests differences be-
tween the 2 viruses in control and location of replication.
4. A critical cofactor of PVAN might be host cell regen-
eration after tubular epithelial cell injury from immunological,
drug-related, mechanical, or ischemic assaults [2, 7, 36]. Rep-
licating tubular epithelial cells in the presence of weakened
immune functions might provide the fertile microenvironment
for high-level BKV replication and organ involvement, whereas
continuously proliferating cells of the urothelial layer readily
support BKV replication without significant injury [2].
In clinical practice, it seems conceivable that patients re-
ceiving a renal allograft infected with BKV (donor positive,
recipient negative) or organs with a high latent load might
develop BKV replication in the absence of potent immuno-
suppression or antirejection treatment, whereas antirejection
treatment might be required for BKV replication in transplant
recipients with a sizeable BKV immune response. Given the
heterogeneity of risk factors and patient characteristics, it is
important to emphasize that stratification of the risk of PVAN
can be done by screening for BKV replication in urine and
plasma. Similar results were obtained in 3 prospective studies
[6, 28, 37] that reported BKV viruria in 30%, 35%, and 28%
of renal transplant recipients. In the 3 studies, BKV viremia
was observed in 13%, 11.5%, and 12.4% of patients and de-
veloped 4–7 weeks after BKV viruria [6, 28, 37]. Because the
sensitivity and negative predictive value of BKV viruria for
PVAN is close to 100%, PVAN can be ruled out in 70%–90%
of patients by use of urine cytology or PCR studies. On the
other hand, if BKV viruria is detected, the risk of PVAN is
increased, and adjunct studies are warranted; persistent BKV
DNA viral loads of 110,000 copies/mL of plasma for 4 weeks
[4, 6, 22] or BKV VP-1 mRNA loads of 1 copies/ng56.5 10
of total RNA [38] were found to be 193% specific and 93%
sensitive for histologically documented PVAN. Screening for
BKV replication in renal transplant recipients is therefore rec-
ommended (1) at least 3 times monthly for the first 2 years
after transplantation, (2) when allograft dysfunction is noted,
and (3) when allograft biopsies are performed for any reason,
including for surveillance [26].
Although allograft biopsy is highly specific (“definitive”
PVAN), it is important to realize that the sensitivity is limited
because of focal involvement, particularly in the early stages,
and because of presentation may be mistaken as acute rejection
or chronic allograft nephropathy. In a careful study, Drach-
enberg et al. [22] observed at least 30% discordant results—
that is, both PVAN-positive and PVAN-negative findings—for
biopsy cores obtained from patients with PVAN at the same
visit. With a working terminology similar to that for invasive
fungal disease, “possible” PVAN is defined as the presence of
BKV viruria, “presumptive” PVAN is defined as a BKV viral
load of 110,000 copies/mL of plasma or by a BKV VP-1 mRNA
level of 1 copies/ng of total urine RNA, and “defin-56.5 10
itive” PVAN is defined as histological evidence of allograft in-
volvement [26]. For patients with “presumptive” PVAN, the
risks and benefits of intervention have not been conclusively
evaluated. However, recent data suggest that progression to
PVAN can be safely prevented if BKV viremia is used as a guide
to reduce immunosuppression [28].
The treatment of PVAN is difficult because of the absence
of specific and well-tolerated antivirals. The current mainstay
of intervention is to reduce the immunosuppressive mainte-
nance therapy. Although no protocol has been formally tested,
3 strategies are currently used that consist of reducing, stopping,
or switching components of the immunosuppressive regimen.
Most centers reduce the calcineurin-inhibitor dosage (target
trough levels for tacrolimus, !6 ng/mL; target for cyclosporine,
!150 mg/mL) and stop or reduce MMF dosage to !50% of the
initial dosage. Switching from tacrolimus to cyclosporine (tar-
get, !150 mg/mL) or to sirolimus (target, !6 ng/mL) or switch-
ing from MMF to leflunomide has been successful in some
cases [6, 39]. Reduction of immunosuppression is controversial
in cases with histological evidence of rejection that may benefit
from a 2-step approach of initial steroid-pulse treatment fol-
lowed by reduced immunosuppression [26]. Some of the pa-
tients may experience an immune reconstitution syndrome dif-
ficult to distinguish from rejection [4].
There is no established antiviral therapy for PVAN. Cidofovir
and leflunomide have BKV-inhibitory activity in vitro, but the
selectivity index appears to be moderate [40]. Replacing MMF
with leflunomide has been successful, but the presumed anti-
viral activity is difficult to dissociate from reduced immuno-
suppression [41, 42]. Cidofovir is transported into tubular ep-
ithelial cells, which explains its nephrotoxicity. BKV does not
encode a viral DNA polymerase, which represents the primary
target of cidofovir in CMV replication. Thus, anti-BKV activity
of cidofovir has characteristics of chemotherapy, because it af-
fects host cell replication to a significant extent [4]. In renal
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transplant recipients, off-label use of cidofovir has been pro-
posed for PVAN at 1/10th or 1/20th of the dosage used to treat
CMV retinitis (0.25–0.33 mg/kg), administered intravenously
every 2 weeks, without probenicid. The success of such treat-
ment was variable and was often coupled with reduced im-
munosuppression. Quinolone antibiotics have been shown to
inhibit SV40 helicase activity in vitro, and the resolution of
BKV replication was observed in a study of 10 renal transplant
recipients [43]. Clearly, prospective, randomized studies are
needed to better define the role of these agents.
Retransplantation after allograft loss due to PVAN has been
successful in a limited number of patients, with recurrences in
2 (15%) of 15 cases. In most of these patients, the same im-
munosuppressive drug regimens were reinstituted, but high-
level treatment was avoided [44]. Although graft nephrectomy
may not be required in principle, a period without immuno-
suppression may be important for the reconstitution of BKV-
specific immune effectors and the clearance of BKV viremia.
This may not readily occur in patients who require continuous
immunosuppression for another graft (e.g., pancreas); thus,
renal allograft removal should be considered for patients with
continuous viremia [45].
Ureter. Ureteral stenosis has been associated with BKV
replication in renal transplant recipients. In some initial clinical
studies and in animal models, histological evidence of BKV
replication in ureteral stenosis was obtained [4, 46]. This com-
plication is now infrequently reported, which could be the result
of decreased local damage due to better surgical techniques,
the routine use of ureteral stents, and underdiagnosis of BKV,
which occurs because surgical reconstruction and histological
evaluations are less frequent and because the BKV etiology may
be more difficult to prove in late pattern C–type fibrosed tissues
[4]. A survey of 1629 consecutive renal transplantations be-
tween 1990 and 2001 identified ureteral stenosis in 52 cases
(3.2%). Delayed graft function, donor age, and CMV infection
were significantly higher among these renal transplant recipi-
ents [47]. Data on the histological work-up were available for
25 cases, revealing thrombosis in 20 cases, ongoing CMV rep-
lication in 4 cases, and ongoing BKV replication in 2 cases.
Whereas these data stress the overall importance of CMV, in-
cluding its importance in vascular and ureteral complications,
they point to a potentially underestimated role of BKV, which
was also highlighted by 2 other case reports [48]. Of note,
Brennan et al. [28] reported that the placement of ureteral
stents was the sole independent parameter associated with sus-
tained BKV viremia (hazard ratio, 4.3; ). It could bePp .045
hypothesized that this procedure may cause sufficient local in-
jury in the urothelial layer and may lead to BKV reactivation
and spread into the circulation.
Bladder. Polyomavirus viruria (the presence of “decoy
cells,” or virions) may be associated with cystitis-like symptoms
in 0.3% of immunocompetent individuals and only occasion-
ally manifests as hemorrhagic cystitis. Hemorrhagic cystitis is
also rare in HIV/AIDS and in solid-organ transplantation but
represents a frequent complication in bone marrow transplan-
tation (incidence, 5%–60%). Early-onset hemorrhagic cystitis
has been linked to toxic effects of the conditioning procedure,
whereas late-onset hemorrhagic cystitis, starting 12 weeks after
transplantation, has been associated with BKV viruria [49].
However, approximately one-half of bone marrow transplant
recipients with BKV viruria do not develop hemorrhagic cys-
titis. Although an association with higher BKV loads has been
reported, the values are scattered and significantly overlap those
found for patients without hemorrhagic cystitis. Moreover,
other viral infections have been associated with hemorrhagic
cystitis, such as adenovirus and CMV, which may even coexist.
We have previously suggested that the pathogenesis of late-
onset hemorrhagic cystitis corresponds to a sequence of events
reminiscent of an immune-reconstitution syndrome [50, 51].
In this model, BKV provides an unspecific but highly prevalent
antigen that becomes abundant because of high-level replica-
tion after conditioning and impaired immune surveillance. Re-
constituted immune effectors engage with abundant BKV an-
tigens and ignite an excessive inflammatory response. The
damage and regeneration of urothelia and the antigen level act
as contributing factors. Adenovirus and CMV can easily be
accommodated in this model as contributing or substituting
antigens. Recent data on significant BKV replication (BKV
DNA load, 1109 copies/mL of urine) and graft-versus-host dis-
ease before late-onset hemorrhagic cystitis are compatible with
this model [52]. Urothelial damage and inflammation may also
enhance the representation of BKV DNA in circulation, ex-
plaining the better positive-predictive value of BKV viremia,
compared with BKV viruria [53], although these data require
broader evaluation. The treatment of hemorrhagic cystitis is
difficult, because no specific antivirals are available. Thus, the
current mainstay is symptomatic treatment, with pain relief,
bladder irrigation, and selective urological intervention. Ci-
dofovir has been used with success for patients with concurrent
CMV infection, but there is a lack of systematic studies. It is
possible that low-dose cidofovir might be a less toxic option.
Recently, the antibiotic ciprofloxacin, a bacterial DNA gyrase
inhibitor, was found at standard doses to reduce the increase
in and the mean urinary level of BKV load in bone marrow
transplant recipients [54]. The rate of hemorrhagic cystitis was
not significantly reduced, but, because the sample size was
small, larger multicenter studies are needed.
CNS. BKV was detected by PCR in the CSF of 3 (1.5%)
of 195 children with suspected encephalitis [55] and in 5 (3.8%)
of 131 adults with suspected viral meningitis and/or encephalitis
that coexisted with signs of systemic illness [56]. In HIV/AIDS,
BKV has been associated with 4 cases of meningoencephalitis
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that represented manifestations of disseminated BKV replica-
tion and disease, including retinitis, pneumonitis, and PVAN,
as reviewed elsewhere [4]. Recently, BKV was the only agent
detected in the CSF of a renal transplant recipient who had
neurological deterioration and for whom findings of imaging
studies suggested progressive multifocal leukoencephalopathy
[57]. Clinical improvement and clearance of BKV viruria was
observed after discontinuation of prednisone therapy and a
switch from MMF to leflunomide. Thus, BKV replication in
individuals with naive or immunosuppressed immune effectors
might be associated with CNS manifestations, but further stud-
ies are needed.
Respiratory tract. BKV has been associated with flulike
symptoms and upper respiratory tract infections in children,
suggesting respiratory transmission [58]. BKV pneumonia
with clinical signs and symptoms was documented in a child
who underwent bone marrow transplantation [59]. No other
pathogen except BKV was isolated from respiratory secretions
before and after transplantation and from postmortem pneu-
monic lung tissue [59]. Also, BKV pneumonia was identified
in autopsies of rare cases of severely immunocompromised
patients with HIV-AIDS who showed disseminated BKV rep-
lication [4, 60].
CONCLUSIONS
BKV requires specific opportunities to unfold its diverse path-
ogenic potential. Profound immunosuppression that permits
high-level BKV replication and organ pathology is the common
hallmark of PVAN in renal transplantation and of hemorrhagic
cystitis in bone marrow transplantation, although the patho-
genesis for each likely differs. The association of BKV with
autoimmune disease and cancer is controversial and requires
the development of more-specific diagnostic tools, independent
of testing for BKV replication.
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